Table 3.
Score summary of the analysed cohort
| |
MDMX - |
MDMX + |
MDMX ++ |
Total | |||
|---|---|---|---|---|---|---|---|
| P53 - | P53 + | P53 - | P53 + | P53 - | P53 + | ||
| MDM2 - |
9* |
2* |
0 |
0 |
0 |
0 |
11 |
| MDM2 + |
3 |
1 |
4 |
0 |
0 |
2† |
10 |
| MDM2 ++ |
4§ |
0 |
12§ |
1§ |
3† |
20† |
40 |
| Total | 19 | 17 | 25 | 61 | |||
Immunohistochemistry scores for MDM2 and MDMX were stratified as follows: (-) normal expression: when <11% of cells had positive nuclear staining; (+) moderate over-expression: when 11 – 40% of cells had positive nuclear staining; (++) strong over-expression: when >40% of cells had positive nuclear staining. Scores for P53 were: (-) negative expression: when ≤10% of cells had positive nuclear staining; (+) positive expression: when 11% or more of cells had positive nuclear staining.
*MDM-P53 pathway is inactive as negative staining for MDM2 and MDMX; § collaborative MDM2 and MDMX pattern with higher MDM2 expression levels resulting in negative P53; † competitive MDM2 and MDMX pattern where comparable levels of MDM2 and MDMX expression lead to positive P53.